Thyrocare Technologies Limited has announced its Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended December 31, 2025. The company reported a consolidated revenue growth of 18% YoY and a 38% YoY growth in Reported EBITDA for Q3 FY26. On a consolidated basis, revenue from operations stood at ₹195.53 crore, a 18% increase from ₹165.92 crore in Q3 FY25. Normalized EBITDA grew by 26% to ₹62.23 crore from ₹49.29 crore, while Reported EBITDA saw a significant jump of 38% to ₹57.64 crore from ₹41.64 crore in the same period. The standalone results for Thyrocare Technologies Limited (TTL) also showed robust growth, with revenue from operations increasing by 20% YoY to ₹182.48 crore from ₹152.55 crore in Q3 FY25. Normalized EBITDA rose by 31% to ₹62.03 crore from ₹47.39 crore, and Reported EBITDA grew by 44% to ₹58.11 crore from ₹40.23 crore. Key operational highlights include a 22% YoY growth in tests conducted to 49.6 million, and a 12% YoY increase in active franchisees to approximately 10,300. The company also reported a significant reduction in complaints per million tests, down 43% YoY to 3.2. The presentation also highlighted strategic pillars for future growth, including deepening reach in India, strengthening franchise networks, expanding partnerships, and growing the presence in Tanzania.
